Pharmacological Therapy

The orexin receptor antagonist suvorexant improves sleep in patients with insomnia, analysis of pooled results of two Phase 3 clinical trials presented at SLEEP 2015 have found.

Administration of a non-benzodiazepine sedative hypnotic (NBSH) does not increase the likelihood of having a low arousal phenotype for obstructive sleep apnea (OSA), a study presented at SLEEP 2015 has concluded.

Chewing caffeine gum for five minutes immediately upon awakening may counter sleep inertia, especially for reaction time, according to a data presented at SLEEP 2015.

Severe obstructive sleep apnea syndrome (OSAS) may potentially be associated with pancreatic β-cell functional disorder and glucagon-like peptide-1 (GLP-1) resistance, according to a study presented at SLEEP 2015.

Reporting on a study of the reaction of children to morphine administration at SLEEP 2015, Gaspard Montandon, PhD, University of Toronto, said that respiratory depression was “more severe when patients were in states of reduced arousal due to the sedative properties of morphine.”

Endogenous pain regulatory function is impacted by sleep duration, according to data presented at SLEEP 2015,

Milnacipran does not directly improve sleep continuity and architecture but its impact on sleep improvement can be attributed to its effectiveness in reducing pain, according to data presented at SLEEP 2015.

When eszopiclone was given instead of zolpidem, no difference was observed on the polysomnogram diagnostic and positive airway pressure (PAP)-titration portions, according to data reported at SLEEP 2015.

An 80-year-old male with new onset myasthenia gravis and narcolepsy with cataplexy had symptomatic improvement with sodium oxybate—but not with immune-modulating agents, results of a case study presented at SLEEP 2015 have shown.

For about one-third of patients treated with zolpidem, only partial improvement is observed, researchers reported at SLEEP 2015.